Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
Sign Up to like & getrecommendations! Published in 2022 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.mct-21-0950
Abstract: Abstract BRAF plus MEK inhibitor combinations are currently FDA-approved for melanoma, non–small cell lung cancer, and anaplastic thyroid cancer. The lack of clinical benefit with BRAF inhibition in BRAF V600–mutated colorectal cancer has prevented its… read more here.
Keywords: braf plus; braf v600; braf; inhibitor ... See more keywords
Intermittent Inhibition of BRAF plus MEK Is Not Beneficial in Melanoma.
Sign Up to like & getrecommendations! Published in 2020 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-rw2020-152
Abstract: Compared with standard continuous dosing, intermittent dosing did not improve patient outcomes. read more here.
Keywords: beneficial melanoma; plus mek; intermittent inhibition; braf plus ... See more keywords